Special Issue "Current Challenges and Future Prospects in Human Reproduction and Infertility"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: 31 August 2023 | Viewed by 907

Special Issue Editors

Center for Reproductive Medicine, University of Liege, Boulevard du 12ème de Ligne 1, 4000 Liege, Belgium
Interests: oncofertility; fertility preservation; implantation failure; ovulatory disorders; endometriosis; infertility; IVF
Obstetrics and Gynecology Department, University of Liege, 4000 Liège, Belgium
Interests: endometriosis; adenomyosis; reproductive surgery; gynecology of childhood and adolescence; malformations of the genital system; uterine myomas

Special Issue Information

Dear Colleagues, 

Reproduction is a vast field of human physiology that remains partly mysterious. Although it can be medicalized to varying degrees, from intrauterine insemination to in vitro fertilization with or without pre-implantation genetic testing, failures are unfortunately frequent and can be tragic for the individuals concerned. The genetic recombination between the oocyte and the spermatozoon at the time of fertilization and the implantation of the embryo in the endometrium are the main black boxes of human reproduction.

Reproductive specialists are constantly looking for ways to enhance the assisted reproductive technologies in order to improve the results obtained while limiting the heaviness of the treatments, particularly their impact on the couple but also on the desired child.

Another important aspect of reproduction is the prevention of infertility. This is especially true as the age of women at first conception continues to increase while individuals are subjected to pollutants and other endocrine disruptors which, combined with a sometimes-inappropriate lifestyle, will alter the chances of conception. Another facet of this fertility preservation concerns the prevention of the toxic effects of certain treatments, such as chemotherapy, but also ovarian surgery. Indeed, preservation of ovarian tissue is challenging for infertile patients suffering from ovarian endometriosis. Different surgical procedures aiming to avoid ovarian reserve damage are nowadays possible.

Given the complexity of this topic and its impact on clinical practice and public health, Medicina is launching a Special Issue entitled Current Challenges and Future Prospects in Human Reproduction and Infertility.

Dr. Laurie Henry
Prof. Dr. Michelle Nisolle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • fertility preservation
  • embryology
  • implantation
  • fertility
  • human reproduction
  • reproductive surgery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
Medicina 2023, 59(3), 517; https://doi.org/10.3390/medicina59030517 - 07 Mar 2023
Viewed by 695
Background and Objectives: The goal of this study was to investigate the effect of selective serotonin reuptake inhibitor treatment on the ovarian reserves of women of reproductive age with major depressive disorder. Materials and Methods: The current study is a prospective [...] Read more.
Background and Objectives: The goal of this study was to investigate the effect of selective serotonin reuptake inhibitor treatment on the ovarian reserves of women of reproductive age with major depressive disorder. Materials and Methods: The current study is a prospective controlled trial including 48 women with major depressive disorder and 48 age-matched healthy controls. Ovarian reserve tests are performed prior to treatment and after six cycles of selective serotonin reuptake inhibitor treatment in the major depressive disorder group. Serum follicle-stimulating hormone, luteinizing hormone, estradiol, and anti-Müllerian hormone levels were evaluated from blood samples, and endometrial thickness, total antral follicle count, and volume of both ovaries were assessed using transvaginal ultrasonography. Results: When the first measurements were compared, menstrual duration and menstrual bleeding increased (p = 0.007 and 0.005, respectively) and luteinizing hormone decreased (p = 0.045) in the major depressive disorder group, while follicle-stimulating hormone, estradiol, anti-Müllerian hormone, endometrial thickness, total antral follicle count, and mean ovarian volume did not differ significantly between groups (p > 0.05). When the major depressive disorder group’s first and final measurements were compared, follicle-stimulating hormone, estradiol, and endometrial thickness increased (p = 0.05, 0.0001, and 0.005, respectively), luteinizing hormone remained constant (p = 0.541), and anti-Müllerian hormone and total antral follicle count decreased (p = 0.024 and 0.042, respectively). Conclusions: In this study, we observed that the ovarian reserve test results of patients diagnosed with major depression for the first time after 6 months of SSRI treatment were significantly different from the results of the pretreatment and control groups. Full article
Show Figures

Figure 1

Back to TopTop